- Home
- EMCG vs RAPT Comparison
EMCG vs RAPT Comparison
Compare EMCG & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- RAPT
- Stock Information
- Founded
- EMCG 2021
- RAPT 2015
- Country
- EMCG United States
- RAPT United States
- Employees
- EMCG N/A
- RAPT N/A
- Industry
- EMCG
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- EMCG
- RAPT Health Care
- Exchange
- EMCG NYSE
- RAPT Nasdaq
- Market Cap
- EMCG 52.4M
- RAPT 59.1M
- IPO Year
- EMCG 2022
- RAPT 2019
- Fundamental
- Price
- EMCG $11.93
- RAPT $1.25
- Analyst Decision
- EMCG
- RAPT Hold
- Analyst Count
- EMCG 0
- RAPT 10
- Target Price
- EMCG N/A
- RAPT $6.00
- AVG Volume (30 Days)
- EMCG 3.4K
- RAPT 616.2K
- Earning Date
- EMCG 01-01-0001
- RAPT 03-06-2025
- Dividend Yield
- EMCG N/A
- RAPT N/A
- EPS Growth
- EMCG N/A
- RAPT N/A
- EPS
- EMCG 0.23
- RAPT N/A
- Revenue
- EMCG N/A
- RAPT N/A
- Revenue This Year
- EMCG N/A
- RAPT N/A
- Revenue Next Year
- EMCG N/A
- RAPT N/A
- P/E Ratio
- EMCG $51.06
- RAPT N/A
- Revenue Growth
- EMCG N/A
- RAPT N/A
- 52 Week Low
- EMCG $11.03
- RAPT $0.79
- 52 Week High
- EMCG $13.39
- RAPT $10.05
- Technical
- Relative Strength Index (RSI)
- EMCG 70.95
- RAPT 53.72
- Support Level
- EMCG $11.80
- RAPT $1.10
- Resistance Level
- EMCG $11.85
- RAPT $1.30
- Average True Range (ATR)
- EMCG 0.00
- RAPT 0.09
- MACD
- EMCG 0.01
- RAPT 0.02
- Stochastic Oscillator
- EMCG 100.00
- RAPT 72.00
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.